Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- PMID: 24142049
- PMCID: PMC5710001
- DOI: 10.1038/nbt.2696
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Abstract
As more clinically relevant cancer genes are identified, comprehensive diagnostic approaches are needed to match patients to therapies, raising the challenge of optimization and analytical validation of assays that interrogate millions of bases of cancer genomes altered by multiple mechanisms. Here we describe a test based on massively parallel DNA sequencing to characterize base substitutions, short insertions and deletions (indels), copy number alterations and selected fusions across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded (FFPE) clinical specimens. We implemented a practical validation strategy with reference samples of pooled cell lines that model key determinants of accuracy, including mutant allele frequency, indel length and amplitude of copy change. Test sensitivity achieved was 95-99% across alteration types, with high specificity (positive predictive value >99%). We confirmed accuracy using 249 FFPE cancer specimens characterized by established assays. Application of the test to 2,221 clinical cases revealed clinically actionable alterations in 76% of tumors, three times the number of actionable alterations detected by current diagnostic tests.
Conflict of interest statement
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: details are available in the online version of the paper.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5710001/bin/nihms917902f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5710001/bin/nihms917902f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5710001/bin/nihms917902f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5710001/bin/nihms917902f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5710001/bin/nihms917902f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5710001/bin/nihms917902f6.gif)
Comment in
-
Next-generation sequencing in the clinic.Nat Biotechnol. 2013 Nov;31(11):990-2. doi: 10.1038/nbt.2743. Nat Biotechnol. 2013. PMID: 24213773 No abstract available.
Similar articles
-
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.Virchows Arch. 2018 Oct;473(4):489-503. doi: 10.1007/s00428-018-2411-4. Epub 2018 Aug 13. Virchows Arch. 2018. PMID: 30105577 Free PMC article.
-
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.Oncotarget. 2016 Oct 18;7(42):68206-68228. doi: 10.18632/oncotarget.11910. Oncotarget. 2016. PMID: 27626691 Free PMC article.
-
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11. Cancer Gene Ther. 2015. PMID: 26358176 Review.
-
A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine.Ann Oncol. 2015 Sep;26(9):1830-1837. doi: 10.1093/annonc/mdv184. Epub 2015 Apr 21. Ann Oncol. 2015. PMID: 25899787 Review.
-
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.J Mol Diagn. 2014 Jan;16(1):56-67. doi: 10.1016/j.jmoldx.2013.08.004. Epub 2013 Nov 2. J Mol Diagn. 2014. PMID: 24189654 Free PMC article.
Cited by
-
Targeting FGFR for cancer therapy.J Hematol Oncol. 2024 Jun 3;17(1):39. doi: 10.1186/s13045-024-01558-1. J Hematol Oncol. 2024. PMID: 38831455 Free PMC article. Review.
-
Prediction of Mismatch Repair Status in Endometrial Cancer from Histological Slide Images Using Various Deep Learning-Based Algorithms.Cancers (Basel). 2024 May 9;16(10):1810. doi: 10.3390/cancers16101810. Cancers (Basel). 2024. PMID: 38791889 Free PMC article.
-
Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series.Ther Adv Med Oncol. 2024 May 19;16:17588359241253113. doi: 10.1177/17588359241253113. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38770091 Free PMC article.
-
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors.PLoS One. 2024 May 16;19(5):e0302129. doi: 10.1371/journal.pone.0302129. eCollection 2024. PLoS One. 2024. PMID: 38753705 Free PMC article.
-
Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary.J Cancer Res Clin Oncol. 2024 May 15;150(5):256. doi: 10.1007/s00432-024-05783-6. J Cancer Res Clin Oncol. 2024. PMID: 38750402 Free PMC article.
References
-
- Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010;87:543–552. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials